Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Nelson L. Michael, Keith Meyer et al.|The Lancet|2017Cited by 196
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorVincent Dussupt, Nelson L. Michael, Rajeshwer S. Sankhala et al.|Nature Medicine|2020Cited by 88
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trialKirsten E. Lyke, Robert Edelman, Joel V. Chua et al.|The Lancet Infectious Diseases|2024Cited by 24
Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical TrialLeyi Lin, Stephen J. Thomas, Michael Koren et al.|The Journal of Infectious Diseases|2020Cited by 24
Does prior dengue virus exposure worsen clinical outcomes of Zika virus infection? A systematic review, pooled analysis and lessons learnedJennifer Masel, Simon Pollett, Michael K. McCracken et al.|PLoS neglected tropical diseases|2019Cited by 23